Development and Validation of RP-HPLC Method for the Dissolution Study of Bosentan in Bulk and in Pharmaceutical Dosage Form
Article Sidebar
Main Article Content
Abstract
A simple, sensitive, precise and accurate reversed phase high performance liquid chromatographic(RP-HPLC) method has been developed for the dissolution study of Bosentan in bulk and in pharmaceutical dosage forms. The method was developed using the mobile phase comprising of Triethylamine buffer pH adjusted to 2.5 with ortho phosphoric acid and acetonitrile in the ratio of 50:50 v/v over Waters Symmetry C8 column (150 mm length x 4.6 mm i.d x 5 μm particle size) at temperature 40 ํC. The flow rate was 1.5 ml/ min and UV detection was at 266 nm. The retention time of Bosentan was 4.475 mins. The recovery was found to be 99.98 % which is demonstrative of accuracy of the protocol. Inter-day and intra-day precisions of the newly developed method were less than the maximum allowable limit (%RSD < 2) according to ICH guidelines. The method showed linearity in the concentration range of 35-210 μg/ ml with correlation coefficient(r2) value of 0.9999. No interference was observed from the blank (dissolution medium) and placebo samples. Hence the method was specific for determination of % release of Bosentan tablets in dissolution study. In robustness study for dissolution condition there was no significant change was observed in % release after individually changing the dissolution parameters. Calculations for system suitability parameters met the acceptance criteria. The percentage drug release was found to be 99.41 % for marketed Bosentan tablet. Several trials were performed by changing the dissolution medium; the 1 % SLS dissolution medium shows successful drug release. All the validation parameters were within the acceptance range. Therefore, the method was found to be simple, precise, accurate, reproducible, sensitive and less time consuming and can be successfully applied for routine quality control and analysis and dissolution study of Bosentan in bulk and in pharmaceutical dosage form.
Keywords: Bosentan, RP-HPLC, Method development, Validation, ICH guidelines, Dissolution studies.
*Corresponding author: Tel.: +91 9443454675 Fax: +914288-234417
E-mail: anandkarunakaran@gmail.com
Article Details
Copyright Transfer Statement
The copyright of this article is transferred to Current Applied Science and Technology journal with effect if and when the article is accepted for publication. The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, electronic form (offline, online) or any other reproductions of similar nature.
The author warrants that this contribution is original and that he/she has full power to make this grant. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors.
Here is the link for download: Copyright transfer form.pdf
References
[2] https://livertox.nih.gov/Bosentan.htm/ dated 15.10.2017.
[3] www.rxlist.com/tracleer-drug/warnings-precautions.htm/ dated 15.10.2017.
[4] www.drugbank.ca/drugs/DB00559/ dated 15.10.2017.
[5] https://www.drugs.com/cdi/bosentan.html/ dated 15.10.2017.
[6] http://www.chemspider.com/Chemical-Structure.94651.html/ dated 15.10.2017.
[7] Sweetmar, S.C., 2011. Martindale: The complete Drug Reference. USA: Pharmaceutical Press.
[8] https://en.wikipedia.org/wiki/Bosentan.htm/ dated 15.10.2017.
[9] Maryadele, J., Heckelman, P.E. eds., 2006. The Merck Index. USA: Merck Research Laboratories.
[10] Ashok kumar, A., Anil kumar, A. and Gouri sankar, D., 2011. Development, estimation and validation of Bosentan in bulk and in its pharmaceutical formulation by UV-Visible spectroscopic method. Int. J. Pharm and Bio Science, 2(2), 225-230.
[11] Narendra, A., Deepika, D. and Mathrusriannapurna, M., 2012. New spectrophotometric method for the determination of Bosentan an anti-hypertensive agent in pharmaceutical dosage form. Eur. J. Chem., 9 (2), 700-704.
[12] Shaik, M., Saidulu, P., Tejaswini, I.S. and Annapurna, U., 2014. Development of new validated analytical methods for the estimation of bosentan in bulk and pharmaceutical dosage form by UV spectrophotometry. W. J. of Pharm. Res., 3(4), 509-516.
[13] Karnaker reddy, T., Younus, M.D., Ravindra reddy, Y., Ashwini kumar, G. and Sravan, S.,2011. RP-HPLC method development and validation of Bosentan drug present in tablets. Int.J. Pharm. Tech., 2(3), 577-587.
[14] Muralidharan, S. and Kumar, J.R., 2012. Simple estimation of Bosentan in tablet formulation by RP-HPLC. Ame. J. Anal. Chem., 3, 715-718.
[15] Sujatha, K., Palavan, C. and Seshagiri Rao, J.V.L.N., 2013. A new validated RP-HPLC method for the estimation of Bosentan in tablet dosage forms. Ame. J. Pharm. Tech., 3 (4),675-680.
[16] Lavudu, P., Rani, A.P., Chander, P. and Sekaran, C.B., 2013. Determination of Bosentan in pharmaceutical dosage forms by high performance liquid chromatography. Int. J. Drug Del.,5(2), 146-151.
[17] Kalaichelvi, R. and Jayachandran, E., 2013. Estimation of Bosentan in pure and tablet dosage form by RP-HPLC. Int. J. Pharm. Chem. Scien., 2(2), 837-840.
[18] Lavudu, P., Rani, A.P., Sekaran, C.B., Ramesh, A. and Kumar, A., 2014. Application of spectrophotometry and high performance liquid chromatography for the analysis of Bosentan in pharmaceutical dosage form. Chem. Sci. Transaction., 3(4), 1242-1253.
[19] Khan, M.A., Sinha, S., Todkar, M., Parashar, V. and Swamy Reddy, K., 2012. Development and validation of a stability indicating analytical method for the related substances of Bosentan drug substance by HPLC. Ame. J. Scien. Ind. Res., 3(2), 69-80.
[20] Rizwan, S.H., GirijaSastry, V. and Imad, Q., 2015. Stability indicating method development and validation of Bosentan in bulk drug and formulation by RP-HPLC method. Int. J.Pharm. Tech. Res., 8(4), 569-579.
[21] Lakshmi Madhuri, B., Yadav, S. and Rao, J., 2016. RP HPLC stability indicating method development and validation for the determination of Bosentan in bulk and pharmaceutical dosage form. Der Pharma Lett., 8(2), 487-495.
[22] Marolia, B.P., Shailesh Shah, A., Kunjan Bodiwala, B., Pintu Prajapati, B. and Hemakshi Jariwala, P., 2015. Development and validation of stability indicating HPTLC method for estimation of Bosentan monohydrate in tablet dosage form. J. Pharm. App. Sci., 2(1), 29-35.
[23] Nataraj, K.S., Narasimharaju Raju, G.N.V.S., Srinivas Rao, A., Sai Kumar, S.V., Divya, S.,and Alekhya, K., 2015. Method development and validation for impurity profiling of Bosentan monohydrate using a novel RP-HPLC method. E. J. Pharm. Med. Res., 2(3), 526-544.
[24] Sivasaikiran, B., Nayudamma Chowdary, Y., Sreelakshmi, V., Shrivastava, S.K., and Pugazhendhy, S., 2014. Development and validation of a headspace gas chromatographic method for determination of residual solvents in Bosentan monohydrate. Int. J. Pharm. Tech Res., 6(2), 421-427.
[25] Paul Richard, M.; Haseena, S.; Swarnalatha, G.; Vanitha, C.; Vijayakumar, B.; Prakash, M.,2015. Development and validation of a headspace gas chromatographic method for determination of residual solvents in Bosentan monohydrate pure drug. Asian J. Pharm. Res., 5 (1), 29-36.
[26] Atila, A., Ozturkb, M.; Kadioglua, Y., Halici, Z., Turkana, D., Yaylac, M. and Und, H.,2014. Development and validation of UFLC–MS/MS method for determination of Bosentan in rat plasma. J. Pharm. Bio-med Anal., 97, 33-38.
[27] ICH, Q2 (R1), 2005. Harmonized tripartite guideline validation of analytical procedure, text and methodology, pp.4-5. Retrieved from http:// www.ich.org/ fileadmin/ public website/ICHproducts/ guidelines/ quality/ Q2 R1 Guideline. pdf. 15.10.2017